Arrest in Primitive Erythroid Cell Development Caused by Promoter-specific Disruption of the GATA-1 Gene*

(Received for publication, January 24, 1997, and in revised form, February 17, 1997)

Satoru Takahashi Dagger , Kou Onodera §, Hozumi Motohashi Dagger , Naruyoshi Suwabe Dagger , Norio Hayashi §, Nobuaki Yanai , Yoichi Nabesima par and Masayuki Yamamoto Dagger **

From the Dagger  Center for Tsukuba Advanced Research Alliance and Institute of Basic Medical Sciences, University of Tsukuba, Tennodai, Tsukuba 305, Japan, the § Department of Biochemistry, School of Medicine and  Department of Cell Biology, Institute of Development, Aging and Cancer, Tohoku University, Seiryo-machi, Aoba-ku, Sendai 980-77, Japan, and the par  Department of Molecular Genetics, National Institute of Neuroscience, Ogawa-higashi, Kodaira 187, Japan

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

To elucidate the in vivo function of GATA-1 during hematopoiesis, we specifically disrupted the erythroid promoter of the GATA-1 gene in embryonic stem cells and generated germ line chimeras. Male offspring of chimeras bearing the targeted mutation were found to die by 12.5 days post coitus due to severe anemia while heterozygous females displayed characteristics ranging from severe anemia to normal erythropoiesis. When female heterozygotes were crossed with transgenic males carrying a reporter gene, which specifically marks primitive erythroid progenitors, massive accumulation of undifferentiated erythroid cells were observed in the yolk sacs of the GATA-1-mutant embryos, demonstrating that GATA-1 is required for the terminal differentiation of primitive erythroid cells in vivo.


INTRODUCTION

The transcription factor GATA-1 (1-3) is expressed in erythroid, megakaryocytic, and mast cells (4, 5) as well as in the Sertoli cells of the testis (6). GATA-1 is encoded by the X chromosome (7), and two alternative promoters, which direct GATA-1 expression in distinct cell lineages, have been identified. The 5' promoter specifies expression in Sertoli cells while a downstream promoter located between the first testis-specific exon and the common coding exons of the gene directs the expression of GATA-1 in erythroid cells (8).

Analysis of GATA-1-null embryonic stem (ES)1 cells generated by homologous recombination has revealed that the mutant cells do not contribute to the mature erythroid population in chimeric animals (9). These ES cells also failed to differentiate into mature erythroid cells in vitro (10-12), suggesting that GATA-1 is required for the erythroid differentiation of hematopoietic progenitor cells. However, previous attempts failed to produce germ line transmission of the GATA-1-null allele. Thus, the in vivo role of GATA-1 in erythropoiesis remains to be resolved.

In this study, we enfeebled the GATA-1 gene through a disruption of its hematopoietic promoter in ES cells and generated germ line chimeras to directly address the in vivo effects of the targeted mutation. Our results demonstrate that GATA-1 is required for the terminal differentiation of primitive erythroid cells in vivo, and this work reveals for the first time the consequence of GATA-1 function in primitive erythroid progenitors during development.


EXPERIMENTAL PROCEDURES

GATA-1 Gene Targeting

Genomic clones of the GATA-1 locus were isolated from a mouse 129 SVJ lambda Fix II library (Stratagene). A 5.1-kilobase 5'-fragment and 2.7-kilobase 3'-fragment, which contains the erythroid-specific first exon (IE exon), were cloned into a vector containing a neomycin-resistance gene (neo) cassette to generate the targeting construct. The resultant construct was linearized with HindIII and electroporated into E14 cells as described (13). Clones were selected in G418 (300 µg/ml), expanded, and analyzed by PCR. Homologous recombination was observed at a frequency of ~1/10 G418-resistant clones. Chimeras were generated by injection of C57 BL/6 blastocysts as described previously. Pups and embryos were genotyped by PCR and/or Southern blotting analyses. We determined the sex of these embryos by using PCR amplification of Y chromosome-specific zfy-1 gene (14).

RT-PCR Analysis of Mouse Embryos

RNA from 9.5 days post coitus (dpc) embryos was isolated by single-step RNA extraction system (RNAzol, Tel-Test). First strand cDNA was synthesized using Superscript reverse transcriptase (Life Technologies, Inc.) at 37 °C for 1 h, and 1 µl of this 20-µl reaction mixture was used in PCR reactions. Reaction products were analyzed on 2% agarose gels. Sequences of the primers used and the expected sizes of PCR products are as follows: for erythroid-specific GATA-1, 5'-TAAGGTGGCTGAATCCTCTGCATC and 3'-CCGTCTTCAAGGTGTCCAAGAACGT (expected product 483 bp); and for testis-specific GATA-1, 5'-CGTGAAGCGAGACCATCGTC and the 3'-primer used for the erythroid-specific primer set (expected product 529 bp). Primers for glucose-6-phosphate dehydrogenase were synthesized as described previously (expected product 162 bp; Ref. 15).

Histological Analysis of Newborn Mice and Embryos

Newborn mice were fixed in 10% buffered formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin for histological examination. Embryos were fixed after being dissected free of maternal tissues. beta -Galactosidase (LacZ) activity was detected as described previously (16). After 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside (X-gal) staining, embryos were photographed before embedding in OCT compound (Sakura Finetechnical) and freezing. Cryosections were processed for immunohistochemistry with anti-murine embryonic hemoglobin sera (17), which was kindly provided by Dr. Tadao Atsumi.

Fetal Liver Colony Assays

Fetal liver cells were inoculated into a methyl cellulose culture in the presence of erythropoietin (2 units/ml) (18). After 2 days, the number of colonies formed were counted, colony forming unit-erythroid (CFU-E). Cells were also assayed for the ability to form granulocyte colonies, colony forming unit-granulocyte/macrophage (CFU-GM) in a semi-solid culture supplemented with granulocyte/macrophage-colony stimulating factor, IL-3, and IL-6.


RESULTS

Targeted Disruption of the Mouse GATA-1 Promoter

We prepared a positive/negative selection targeting vector to introduce a neo cassette into the intergenic region between an important regulatory region of the erythroid promoter and the mRNA cap site. GATA factor binding sites located approximately 620 bp 5' to the IE exon (Fig. 1A) have been shown to positively regulate transcription from the IE promoter (19). The insertion of neo was designed to separate the GATA motifs from the IE exon in the hope that the mutation would negatively affect the activity of the IE promoter. In addition, the positive/negative selection targeting vector was designed to transcribe neo in the same orientation as the GATA-1 gene so that the strong promoter directing neo expression might further weaken the activity of the IE promoter through competition (20, 21). Our expectation is that the activity of the IE promoter will be diminished by the combinatorial effects of these two mechanisms, resulting in a specific `knock-down' (rather than a `knock-out') of the erythroid-specific expression of the GATA-1 gene, and possibly lead to a germ line-transmissible targeted mutation.


Fig. 1. Targeted disruption of the mouse GATA-1 promoter. A, targeting strategy. Solid boxes depict exons (IE and IT denote the erythroid- and testis-specific first exons, respectively). The MC-1-neomycin (Neo) gene (large open box) was inserted between the double GATA sequences (round open circle) and IE exon. Probe 1 and Neo probe were used in Southern blotting analysis to detect homologous recombination. Small open box (DT) indicates the diphtheria toxin A gene cassette (26). Southern blot analyses of SacI-digested chromosomal DNA isolated from wild-type (lanes 1 and 3) or mutant (lane 2) ES cell clones hybridized with probe 1 (B) or neo probe (C).
[View Larger Version of this Image (26K GIF file)]

This targeting construct was introduced by electroporation into ES cells, and 20 independent G418-resistant, PCR-positive clones were identified. Southern blot analysis using internal gene-specific and neo probes confirmed the homologous recombination events (Fig. 1, B and C). Three mutant ES cell lines were used for the generation of chimeric offspring. All the ES cell lines gave rise to chimeras. We crossed these chimeras with normal Balb/c mice and one line (No. 78) gave stable germ line transmission. All F1 generation mice from the chimera mouse were found to be of ES cell origin, and the number of litters and sex ratio were in normal range.

Phenotype of Heterozygous Female Mice

F1 progeny were examined by Southern blot and PCR analyses to confirm the presence of the mutated GATA-1 allele. Since the GATA-1 gene is located on the X chromosome, all heterozygous F1 pups were female. These heterozygotes were found to display varying degrees of anemia. Fig. 2A shows GATA-1 heterozygous embryos; their appearance ranges from normal (left) to severely anemic (right). Concordantly, when we analyzed the livers of two heterozygous newborn littermates (panel B), we found that one liver contained a normal number of hematopoietic cells (left), whereas the other displayed a marked reduction in the number of hematopoietic cells (right). These observations indicated that disruption of the GATA-1 gene erythroid promoter seems to cause severe anemia in vivo and that the effect of the knock-down strategy was as anticipated. The heterogeneity of the phenotypes observed in the female heterozygotes may be the result of selective inactivation of the X chromosome (22).


Fig. 2. Variation in the severity of phenotypes exhibited in heterozygous female embryos. A, two female heterozygous 15-dpc embryos are shown. The pale color of the right embryo contrasts sharply with the normal coloring of its sibling. B, histological examination of livers of heterozygous neonates. Few hematopoietic cells are observed in the section on the right as compared with the relatively normal number of cells in the left section.
[View Larger Version of this Image (103K GIF file)]

Mutant Male Embryos Died in Utero Due to Impaired Primitive Erythropoiesis

The heterozygous females were mated with wild-type males to observe the phenotypic effects on mutant males. Surprisingly, no mutant males were observed among the live offspring, and heterozygous female offspring displayed the same varying degrees of anemia that we observed among the F1s. To determine the nature and timing of the presumptive embryonic lethality of the targeted males, we collected and genotyped embryos ranging from 8.5 to 14.5 dpc. A total of 112 pups from 13 litters were analyzed. At 9.5 dpc, mutant male embryos were present in the expected ratio, but already visible defects could be discerned. The yolk sacs of mutant males were noticeably pale and almost no blood vessels were present (Fig. 3A, right). The mutant males (Fig. 3B, right) could be easily distinguished from wild-type (left) or heterozygous female embryos (data not shown) by their distinctive pallor and small size. Embryonic lethality was first detected at 11.5 dpc, and no live mutant male embryos were found by 12.5 dpc.


Fig. 3. Phenotypes of GATA-1.05 mutant male embryos. Visualization of the highly vascularized wild-type yolk sac (panel A, left) and embryo (panel B, left) versus anemic yolk sac and embryo of a mutant male embryo (right) from the same litter at 9.5 dpc of embryogenesis.
[View Larger Version of this Image (99K GIF file)]

The expression levels of erythroid-specific GATA-1 mRNA were analyzed by RT-PCR using RNA samples obtained from 9.5-dpc embryos. Densitometric analysis of the RT-PCR data revealed that the expression of GATA-1 from the IE promoter in the mutant male embryos was less than 5% of the level present in wild-type embryos (Fig. 4A), therefore we will refer to this targeted mutation as the GATA-1.05 mutant allele. These data show that the expression of the GATA-1 gene from the IE promoter is severely impaired, but not extinguished, by the promoter disruption. The phenotype and timing of death in the male mutant embryos led us to conclude that the cause of in utero lethality is due to impaired primitive erythropoiesis.


Fig. 4. RT-PCR analysis of total RNA isolated from mutant male, heterozygous female, and wild-type 9.5-dpc embryos. A, expression of GATA-1 from the IE promoter (E-GATA-1) was examined after 25, 30, and 35 cycles of amplification. Glucose-6-phosphate dehydrogenase was used as the internal control and analyzed after 22, 27, and 32 cycles of amplification. The numbers indicate individual embryos. Lanes 1-3 are mutant male embryos, lanes 4-6 are heterozygous female embryos, and lanes 7-9 are wild-type embryos. B, expression of GATA-1 from IT promoter (T-GATA-1) were examined after 35 cycles of amplification. The same embryo samples used in panel A were used to detect the IT promoter expression. Lanes are arranged the same way as in panel A.
[View Larger Version of this Image (58K GIF file)]

We also analyzed the expression of GATA-1 from the testis-specific promoter (IT promoter) in these embryos. The expression of testis-type GATA-1 mRNA in the mutant embryos was almost identical as that seen in the wild-type embryos (Fig. 4B), indicating that activity of the testis promoter was left intact in our knock-down mice.

Decreased Number of Erythroid Cells and CFU-E in Mutant Fetal Livers

We examined the hematopoietic phenotype in the livers of mutant male embryos. Morphological examination revealed that size of the liver rudiments of mutant male embryos was markedly reduced and that the color was pale in comparison to the livers of wild-type embryos (data not shown). Microscopic analysis revealed that, whereas many erythroid cells should be present in the liver rudiment at 11.5 dpc, virtually none could be detected in the livers of mutant embryos (compare Fig. 5, panels A and B). This seems to reflect the absence of yolk sac hematopoiesis. GATA-1-positive cells were also absent in liver sections from 11.5-dpc GATA-1.05 mutant male (compare panels C and D).


Fig. 5. Decreased number of erythroid cells in mutant fetal livers. Hematoxylin and eosin staining of the liver sections of 11.5-dpc wild-type (A) and GATA-1.05 mutant male (B) embryos are shown. The arrowhead indicates a cluster of hemoglobinized cells. Anti-GATA-1 antibody staining of a 12.5-dpc wild-type embryonic liver section (C) and an 11.5-dpc GATA-1.05 male mutant (D) are also shown. The arrowhead indicates a GATA-1-positive cell.
[View Larger Version of this Image (120K GIF file)]

We also performed in vitro colony assays with these same fetal liver cells. In comparison with wild-type littermates, the GATA-1.05 male mutant livers did not generate any CFU-E at 10.5 dpc (data not shown), and only a small number of CFU-E were recovered at 11.5 dpc (Table I). In contrast, fetal liver cells from either wild-type or mutant embryos produced similar numbers of CFU-GM colonies (Table II). These data indicate that only a small number of erythroid progenitors exist in the liver of the mutant embryos, while the non-erythroid hematopoietic lineages are unaffected by the mutation. The number of CFU-E formed from fetal liver cells of female heterozygous mutants (GATA-1(+/1.05)) accordingly displayed wide variability, again consistent with the hypothesis that the X chromosome is selectively inactivated in hematopoietic progenitor cells.

Table I. Results of the fetal liver CFU-E assays

The numbers shown represent the colony number per liver ± S.E. from 11.5 dpc embryos. Assays were performed in triplicate. Colonies were counted 2 days after plating. The numbers shown represent the colony number per liver ± S.E. from 11.5 dpc embryos. Assays were performed in triplicate. Colonies were counted 2 days after plating.
Genotype
Wild type +/- female  -/Y male
Embryo number

1 52,600  ± 1,350
2 56,200  ± 1,810
3 49,120  ± 6,350
4 2,590  ± 168
5 110,370  ± 611
6 33,410  ± 767
7 18,500  ± 180
8 88,760  ± 3,276
9 109,120  ± 1,210
10 34,020  ± 2,814
11 1,360  ± 164
12 69,750  ± 3,726
13 59,044  ± 4,303
14 72,027  ± 5,819
15 11,175  ± 892

Table II. Results of the fetal liver CFU-GM assays

The numbers shown represent the colony number per liver ± S.E. from 11.5 dpc embryos. Assays were performed in triplicate. Colonies were counted 6 days after plating. The numbers shown represent the colony number per liver ± S.E. from 11.5 dpc embryos. Assays were performed in triplicate. Colonies were counted 6 days after plating.
Genotype
Wild type +/- female  -/Y male
Embryo number

21 207  ± 23
22 1056  ± 102
23 1476  ± 36
24 378  ± 6
25 276  ± 138
26 700  ± 161
28 320  ± 40

GATA-1-deficiency Results in Accumulation of Primitive Erythroid Progenitors

To investigate how primitive hematopoiesis is affected by the lack of GATA-1, we took advantage of a GATA-1 promoter-LacZ transgene, which is transcriptionally active in primitive but not definitive erythroid cells, to specifically mark the primitive erythroid lineage (23). Female mice heterozygous for the GATA-1.05 mutation were crossed with transgenic mice homozygous for the LacZ reporter transgene to generate LacZ-positive embryos harboring the GATA-1.05 mutation (compound mutation designated GATA-1.05::LacZ).

In 8.0-dpc embryos examined by whole mount X-gal staining, no significant difference in either the abundance or distribution of stained erythroid cells was observed between GATA-1.05::LacZ mutant embryos and LacZ-only littermates (data not shown). By 9.5 dpc, however, the number of blue cells detected in the GATA-1.05::LacZ embryos was far greater than that seen in littermates carrying only the reporter transgene (compare panels A and B, Fig. 6). Detailed examination revealed that the absolute number of hematopoietic cells found in the yolk sac, aortic sac, and atrial chamber of the heart was similar in both wild-type and GATA-1.05 mutant embryos. The significant difference was that only a small percent of the hematopoietic cells in the atrial chamber were positive for staining in the LacZ control embryos (panel C), compared with the blue staining seen in virtually all of the hematopoietic cells in the GATA-1.05::LacZ male embryos (panel D). These blue GATA-1-positive cells express only a limited amount, if any, of embryonic hemoglobin as visualized by an embryonic hemoglobin anti-sera. It should be noted that, consistent with the whole mount analysis described above, virtually all hematopoietic cells in the yolk sac blood islands of 8.5-dpc LacZ transgenic mouse embryos were blue regardless of whether they carried the GATA-1.05 or wild-type allele (data not shown), confirming the specific expression of the reporter GATA-1/LacZ transgene in undifferentiated primitive hematopoietic progenitors. Therefore, in the GATA-1.05 mutant background, it seems that primitive hematopoietic progenitors develop to the GATA-1-positive stage but subsequently cannot differentiate into normal hemoglobinized cells.


Fig. 6. GATA-1 deficiency causes accumulation of primitive erythroid progenitors. X-gal staining of GATA-1 promoter-LacZ transgene in 9.5-dpc wild-type (A) and mutant male (B) embryos. The blue color produced by reaction with the beta -galactosidase substrate can be observed in embryos of both genotypes, but the intensity detected in mutant males appears to be more prominent than that in wild-type embryos. The size of the GATA-1.05 mutant embryo (B) is much smaller than that of the wild-type embryo (A). X-gal staining was combined with anti-embryonic hemoglobin antibody staining on both types of embryos. While many embryonic hemoglobin antibody-positive cells are present in the atrial chambers of wild-type embryos (panel C, brown), few can be seen in the atrial chambers of mutant male embryos (D) even though numerous X-gal-positive (blue) cells are present. The arrowheads in panels A and C indicate hemoglobinized cells. Original magnifications are × 200 (panels C and D).
[View Larger Version of this Image (80K GIF file)]


DISCUSSION

We show here that a modified gene targeting strategy can be successfully employed to dissect the complex roles played by GATA-1 in vivo. This strategy consisted of two components. The first is promoter-specific impairment (knock-down) of transcription factor gene activity, and the second is the lineage- and stage-specific marking of the lineage of target cells that specifically require the function of the transcription factor. The combination of these two approaches enabled us to identify the precise stage of maturation arrest within the primitive erythroid lineage that resulted as a direct consequence of the lowered levels of GATA-1. The in vivo approach described here may be applied to the analysis of any gene of interest with well characterized regulatory regions.

We are able to detect the accumulation of primitive erythroid progenitors in the yolk sac of the GATA-1-mutant embryos, demonstrating that GATA-1 is necessary for the differentiation, but not the formation, of primitive erythroid progenitors. These results are especially intriguing and contrast with the conclusions of a previous report (24). Using in vitro differentiation of GATA-1-null ES cells, Weiss et al. (11) failed to detect primitive erythroid precursors, leading them to conclude that GATA-1 is essential at the earliest stage of primitive erythropoiesis definable by then current methods. In contrast, we observed numerous primitive erythroid progenitors in the yolk sacs and atrial chambers of GATA-1.05 mutant embryos, and the erythroid enhancer of GATA-1 seems active in the progenitor cells. Two possibilities could account for this discrepancy. First, it is possible that a cell lacking GATA-1 may be able to survive in vivo but not under in vitro conditions (24). Alternatively, the residual 5% activity displayed by GATA-1 in the 1.05 mutant allele might be sufficient for cell survival but not for promoting terminal differentiation. We favor the former hypothesis since the knock-down effect on erythropoiesis seems to be clonal, and not uniform, in the erythroid cells (some weakly hemoglobinized cells in the yolk sac of the mutant embryos are routinely detected).

In this regard, it should be noted that Fujiwara et al. (25) recently reported the germ line transmission of a GATA-1-null allele. In that study, the second exon of the GATA-1 gene was disrupted in ES cells, as was the method employed in several previous trials (9-12), and thus the reasons for the failure to generate germ line chimeras using the original GATA-1-disrupted ES cells prepared for previous studies remains unclear. In agreement with the present analysis, male mice bearing the GATA-1-null allele (i.e. -/Y genotype) died by 11.5 dpc of embryogenesis. The coincidence of the null and knock-down mutant phenotypes suggests that the knock-down strategy resulted, as anticipated, in enfeebling the gene to such an extent that its final activity was very close to that of a null mutation, while analysis of the Sertoli GATA-1 transcript indicates that its synthesis, as also anticipated, is unaffected by the GATA-1.05 mutation. Fujiwara et al. (25) also found accumulation of embryonic erythroid cells in GATA-1-null embryos and suggested that the inability to detect embryonic erythroid precursors in prior in vitro experiments reflected a limitation of cell culture assays. Finally, they suggested that the accumulated cells in the yolk sac of the null mutant mouse were arrested at the proerythroblast stage based on morphological examination. In contrast, the present study provides direct evidence for the accumulation of primitive erythroid progenitors in the yolk sac blood islands through an intercross experiment performed by breeding the GATA-1.05 mutant allele to a separate line of mice bearing a transgene that specifically marked the primitive erythroid lineage. As additional evidence, we were able to unequivocally identify the arrested cells as primitive erythroid progenitors using both anti-GATA-1 and anti-embryonic hemoglobin antibodies.

In addition to the primitive erythroid lineage analysis, preliminary studies on the effect of GATA-1 mutation on fetal liver (definitive) erythropoiesis in vivo are presented here for the first time, and we also found this developmental process to be severely affected by the knock-down mutation. The mutant fetal livers were observed to contain only a small number of CFU-E. Since we detected comparable numbers of CFU-GM in either GATA-1(+) or GATA-1.05 mutant mice, the GATA-1 deficiency appears to specifically promote the growth, or prevent apoptosis, in definitive erythroid progenitors. However, we cannot completely rule out the indirect physiological influence (e.g. through hypoxia) that may result from the lack of primitive erythropoiesis. Gene rescue and/or selective inactivation experiments will be necessary to further refine the specific roles played by GATA-1 in definitive hematopoiesis in vivo.


FOOTNOTES

*   This work was supported by the Grants-in-Aid from the Ministry of Education, Science and Culture, Japanese Society for Promotion of Sciences, and the Uehara Memorial Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
**   To whom correspondence should be addressed: Institute of Basic Medical Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba 305, Japan. Tel.: 81-298-53-3111; Fax: 81-298-53-6965; E-mail: masiya{at}igaku.md.tsukuba.ac.jp.
1   The abbreviations used are; ES, embryonic stem; CFU-E, colony forming unit-erythroid; CFU-GM, colony forming unit-granulocyte/macrophage; dpc, days post coitus; IE exon or promoter, erythroid-specific first exon or promoter, respectively; IT exon or promoter, testis-specific first exon or promoter, respectively; LacZ, beta -galactosidase; neo, neomycin-resistance gene; X-gal, 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside; bp, base pair; IL, interleukin; PCR, polymerase chain reaction; RT-PCR, reverse transcriptase-PCR.

ACKNOWLEDGEMENTS

We thank Drs. R. Yu (Nara Advanced Institute of Science and Technology), T. Atsumi (RIKEN), K. Igarashi (Center for Tsukuba Advanced Research Alliance), K. Araki (Kumamoto University), E. Ito (Hirosaki University), Y-K. Nabeshima (National Institute of Neuroscience), N. Kasai, T. Ono, and M. Obinata (Tohoku University) for help and discussion.


REFERENCES

  1. Evans, T., and Felsenfeld, G. (1989) Cell 58, 877-885 [Medline] [Order article via Infotrieve]
  2. Tsai, S. F., Martin, D. I. K., Zon, L. I., D'Andrea, A. D., Wang, G. G., and Orkin, S. H. (1989) Nature 339, 446-451 [CrossRef][Medline] [Order article via Infotrieve]
  3. Bungert, J., and Engel, J. D. (1995) Ann. Med. 28, 47-55
  4. Martin, D. I. K., Zon, L. I., Mutter, G., and Orkin, S. H. (1990) Nature 344, 444-447 [CrossRef][Medline] [Order article via Infotrieve]
  5. Romeo, P.-H., Prandini, M. H., Joulin, V., Mignotte, V., Prenant, M., Vainchenker, W., Marguerie, G., and Uzan, G. (1990) Nature 344, 447-449 [CrossRef][Medline] [Order article via Infotrieve]
  6. Yomogida, K., Ohtani, H., Harigae, H., Ito, E., Nishimune, Y., Engel, J. D., and Yamamoto, M. (1994) Development 120, 1759-1766 [Abstract/Free Full Text]
  7. Zon, L. I., Tsai, S. F., Burgess, S., Matsudaira, P., Bruns, G. A., and Orkin, S. H. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 668-672 [Abstract]
  8. Ito, E., Toki, T., Ishihara, H., Ohtani, H., Gu, L., Yokoyama, M., Engel, J. D., and Yamamoto, M. (1993) Nature 362, 466-468 [CrossRef][Medline] [Order article via Infotrieve]
  9. Pevny, L., Simon, M. C., Robertson, E., Klein, W. H., Tsai, S. F., D'Agani, V., Orkin, S. H., and Constantini, F. (1991) Nature 349, 257-260 [CrossRef][Medline] [Order article via Infotrieve]
  10. Simon, M. C., Pevny, L., Wiles, M. V., Keller, G., Costantini, F., and Orkin, S. H. (1992) Nat. Genet. 1, 92-103 [Medline] [Order article via Infotrieve]
  11. Weiss, M. J., Keller, G., and Orkin, S. H. (1994) Genes & Dev. 8, 1184-1197 [Abstract]
  12. Pevny, L., Lin, C-S., D'Agati, V., Simon, M. C., Orkin, S. H., and Constantini, F. (1995) Development 121, 163-172 [Abstract/Free Full Text]
  13. Hooper, M., Hardy, K., Handyside, A., Hunter, S., and Monk, M. (1987) Nature 326, 292-295 [CrossRef][Medline] [Order article via Infotrieve]
  14. Koopman, P., Gubbay, J., Vivian, N., Goodfellow, P., and Lovell-Badge, R. (1991) Nature 351, 117-121 [CrossRef][Medline] [Order article via Infotrieve]
  15. Boehm, T., Spillantini, M.-G., Sofroniew, M. V., Surani, M. A., and Rabbitts, T. H. (1991) Oncogene 6, 695-703 [Medline] [Order article via Infotrieve]
  16. Byrne, C., and Fuchs, E. (1993) Mol. Cell. Biol. 13, 3176-3190 [Abstract]
  17. Miwa, Y., Atumi, T., Imai, N., and Ikawa, Y. (1991) Development 111, 543-549 [Abstract]
  18. Okuyama, R., Koguma, M., Yanai, N., and Obinata, M. (1995) Blood 86, 2590-2597 [Abstract/Free Full Text]
  19. Tsai, S. F., Strauss, E., and Orkin, S. H. (1991) Genes & Dev. 5, 919-931 [Abstract]
  20. Kim, C. G., Epner, E., Forrester, W. C., and Groudine, M. (1992) Genes & Dev. 6, 928-938 [Abstract]
  21. Choi, O-R. B., and Engel, J. D. (1988) Cell 55, 17-26 [Medline] [Order article via Infotrieve]
  22. Lyon, M. F. (1961) Nature 190, 372-373
  23. Onodera, K., Takahashi, S., Nishimura, S., Ohta, J., Motohashi, H., Yomogida, K., Hayashi, N., Engel, J. D., and Yamamoto, M. (1997) Proc. Natl. Acad. Sci. U. S. A., in press
  24. Weiss, M. J., and Orkin, S. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9623-9627 [Abstract]
  25. Proc. Natl. Acad. Sci. U. S. A. (1996) 12355-12358Fujiwara, Y., Browne, C. R., Cunniff, K., Goff, S. C., and Orkin, S. H. Proc. Natl. Acad. Sci. U. S. A. (1996) 12355-12358
  26. Yagi, T., Nada, S., Watanabe, N., Tatemoto, H., Kohmura, N., Ikawa, Y., and Aizawa, S. (1993) Anal. Biochem. 214, 77-86 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.